Novartis AG NVS on Wednesday secured the U.S. Food and Drug Administration (FDA) approval for Rhapsido (remibrutinib) to ...

Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. Read ...

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include ​a second indication, symptomatic ...

Panelist discusses how hidradenitis suppurativa’s early detection is challenging due to misdiagnosis, patient stigma, and limited awareness. Improved physician education, proactive screening, and ...

Spyre Therapeutics announces pricing of a $350 million public offering to advance immunology therapies and clinical programs.

Researchers found the spread of cancer was lower among six cancer types in patients taking GLP-1 drugs—a statistically ...

NOTRD continues to provide easy-to-understand introductions to research in order to deliver useful information to patients ...

NOTRD continues to provide easy-to-understand introductions to research in order to deliver useful information to patients ...

Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by ...

Researchers found the spread of cancer was lower among six cancer types in patients taking GLP-1 drugs—a statistically ...

Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to ...

Poster Session Session Title: Late-Breaking Research Posters [LB-PO] Session Date, Time: October 22, 2026 from 10:00 AM to 12 ...